JP7832430B2 - 重症急性呼吸器症候群コロナウイルス２のヌクレオカプシドタンパク質に特異的に結合する抗体又はその断片、及びその用途 - Google Patents

重症急性呼吸器症候群コロナウイルス２のヌクレオカプシドタンパク質に特異的に結合する抗体又はその断片、及びその用途

Info

Publication number
JP7832430B2
JP7832430B2 JP2022559219A JP2022559219A JP7832430B2 JP 7832430 B2 JP7832430 B2 JP 7832430B2 JP 2022559219 A JP2022559219 A JP 2022559219A JP 2022559219 A JP2022559219 A JP 2022559219A JP 7832430 B2 JP7832430 B2 JP 7832430B2
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
sequence shown
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022559219A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022092181A1 (https=
Inventor
隆司 川畑
宇洋 枡屋
光佑 柚原
研吾 西村
宏明 北澤
敏弘 黒板
正治 磯部
信幸 黒澤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyobo Co Ltd
University of Toyama NUC
Original Assignee
Toyobo Co Ltd
University of Toyama NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyobo Co Ltd, University of Toyama NUC filed Critical Toyobo Co Ltd
Publication of JPWO2022092181A1 publication Critical patent/JPWO2022092181A1/ja
Application granted granted Critical
Publication of JP7832430B2 publication Critical patent/JP7832430B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Pulmonology (AREA)
JP2022559219A 2020-10-30 2021-10-28 重症急性呼吸器症候群コロナウイルス２のヌクレオカプシドタンパク質に特異的に結合する抗体又はその断片、及びその用途 Active JP7832430B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020183273 2020-10-30
JP2020183273 2020-10-30
PCT/JP2021/039754 WO2022092181A1 (ja) 2020-10-30 2021-10-28 重症急性呼吸器症候群コロナウイルス２のヌクレオカプシドタンパク質に特異的に結合する抗体又はその断片、及びその用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026015215A Division JP2026071287A (ja) 2020-10-30 2026-02-02 重症急性呼吸器症候群コロナウイルス２のヌクレオカプシドタンパク質に特異的に結合する抗体又はその断片、及びその用途

Publications (2)

Publication Number Publication Date
JPWO2022092181A1 JPWO2022092181A1 (https=) 2022-05-05
JP7832430B2 true JP7832430B2 (ja) 2026-03-18

Family

ID=81381499

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022559219A Active JP7832430B2 (ja) 2020-10-30 2021-10-28 重症急性呼吸器症候群コロナウイルス２のヌクレオカプシドタンパク質に特異的に結合する抗体又はその断片、及びその用途

Country Status (5)

Country Link
US (1) US20240288427A1 (https=)
EP (1) EP4239068A4 (https=)
JP (1) JP7832430B2 (https=)
CN (1) CN116437931A (https=)
WO (1) WO2022092181A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023128698A (ja) * 2022-03-04 2023-09-14 公立大学法人横浜市立大学 変異株を含む、体液中のＳＡＲＳ－ＣｏＶ－２抗原に対する抗ＳＡＲＳ－ＣｏＶ－２抗体、該抗体を用いてＳＡＲＳ－ＣｏＶ－２を検出する方法、および該抗体を含むキット
KR20250140089A (ko) * 2023-02-08 2025-09-24 덴카 주식회사 SARS-CoV-2의 검출 방법 및 이를 위한 키트

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111458520A (zh) 2020-04-10 2020-07-28 中国人民解放军军事科学院军事医学研究院 新型冠状病毒AlphaLISA抗原快速检测试剂盒
CN111733141A (zh) 2020-06-19 2020-10-02 清华大学深圳国际研究生院 一种可分泌抗新型冠状病毒n蛋白单克隆抗体的杂交瘤细胞、单克隆抗体及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5779502B2 (ja) 2009-09-04 2015-09-16 国立大学法人富山大学 標的遺伝子由来配列を含む連結ｄｎａ断片の特異的作製方法
KR20130079362A (ko) 2010-03-25 2013-07-10 내셔날 유니버시티 코포레이션 유니버시티 오브 토야마 형질 세포 동정 및 단리용 형광 프로브 및 이 프로브를 이용한 형질 세포의 동정 또는 단리방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111458520A (zh) 2020-04-10 2020-07-28 中国人民解放军军事科学院军事医学研究院 新型冠状病毒AlphaLISA抗原快速检测试剂盒
CN111733141A (zh) 2020-06-19 2020-10-02 清华大学深圳国际研究生院 一种可分泌抗新型冠状病毒n蛋白单克隆抗体的杂交瘤细胞、单克隆抗体及应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KANG, S. et al.，A COVID-19 antibody curbs SARS-CoV-2 nucleocapsid protein-induced complement hyper-activation，bioRxiv，2020年09月11日，URL: https://doi.org/10.1101/2020.09.10.292318，[retrieved on 12.28.2021]
SHROCK, E. et al.，Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity，Science，2020年09月29日，Vol. 370:eabd4250，pp. 1-15, Supplementary Materials
TERRY, J. S. et al.，Development of SARS-CoV-2 Nucleocapsid Specific Monoclonal Antibodies，bioRxiv，2020年09月03日，URL: https://doi.org/10.1101/2020.09.03.280370，[retrieved on 12.28.2021]
WANG, H. et al.，SARS-CoV-2 Proteome Microarray for Mapping COVID-19 Antibody Interactions at Amino Acid Resolution，ACS Cent. Sci.，2020年10月21日，Vol. 6，pp. 2238-2249
新井 浩司，緊急連載「新型コロナウイルスと分析化学」，ぶんせき，日本分析化学会，2020年09月，２０２０年９月号，pp. 320-325

Also Published As

Publication number Publication date
CN116437931A (zh) 2023-07-14
JPWO2022092181A1 (https=) 2022-05-05
EP4239068A4 (en) 2025-01-22
EP4239068A1 (en) 2023-09-06
US20240288427A1 (en) 2024-08-29
WO2022092181A1 (ja) 2022-05-05

Similar Documents

Publication Publication Date Title
Wu et al. Viral mimicry of interleukin-17A by SARS-CoV-2 ORF8
André et al. Proteomic analysis of the tetraspanin web using LC‐ESI‐MS/MS and MALDI‐FTICR‐MS
JP7832430B2 (ja) 重症急性呼吸器症候群コロナウイルス２のヌクレオカプシドタンパク質に特異的に結合する抗体又はその断片、及びその用途
CA2947404A1 (en) Anti-muc1 antibody or antigen-binding fragment thereof and uses thereof
WO2000007023A1 (fr) Procede pour la determination de l'hepatite a virus de type c
US9453070B2 (en) Methods for detecting Th1 cells
Li et al. Identification and characterization of monoclonal antibodies against the ORFV059 protein encoded by Orf virus
CN104181305B (zh) 抗人中性粒细胞明胶酶相关脂质运载蛋白抗体及其用途
CN120005026A (zh) 抗b7-h3单克隆抗体、杂交瘤细胞株及其应用
Xiao et al. Oligomerization of the SARS-CoV S glycoprotein: dimerization of the N-terminus and trimerization of the ectodomain
KR101969696B1 (ko) 메르스 코로나 바이러스 스파이크 s2 단백질에 특이적으로 결합하는 단클론 항체
KR101374758B1 (ko) 항-사이토케라틴 8/18 복합체 자가면역항체를 포함하는 암 진단 마커 및 이의 항원을 포함하는 암 진단용 조성물
JP2026071287A (ja) 重症急性呼吸器症候群コロナウイルス２のヌクレオカプシドタンパク質に特異的に結合する抗体又はその断片、及びその用途
EP4206221A1 (en) Viral infection determination method
CN117603348B (zh) 抗新型冠状病毒s蛋白的全人源化抗体及其应用
CN103665153B (zh) 一种抗流感病毒广谱中和性的中和分子1e1
Gal-Tanamy et al. HCV NS3 serine protease-neutralizing single-chain antibodies isolated by a novel genetic screen
CN110655580B (zh) 一种杂交瘤细胞株及其用途
KR102007161B1 (ko) 메르스 코로나 바이러스 스파이크 s1 단백질에 특이적으로 결합하는 단클론 항체
CN103665156B (zh) 一种抗流感病毒广谱中和性的结合分子3e1
CN107860925B (zh) 用于检测血清中HuA21抗体的ELISA检测试剂盒
CN118834292B (zh) 识别新型冠状病毒表面棘突蛋白s中独有特异性b细胞抗原表位的鲨鱼单域抗体及应用
CN118930643B (zh) 副流感3型np蛋白抗体6d3
JP7794605B2 (ja) 抗体の製造方法及び抗体
JP5114637B2 (ja) 小細胞肺癌の判定方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251020

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260204

R150 Certificate of patent or registration of utility model

Ref document number: 7832430

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150